Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Radiation Therapy in Urothelial Bladder Cancer
NCT02891161Phase 2Terminated
- Start
- Nov 2016
- Primary completion
- Aug 2019
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 2, open-label trial of durvalumab in urothelial carcinoma (UC) (2 arms). Primary endpoints: Dose Limiting Toxicity Rate at 2 years, Progression Free Survival Rate at 1 Year and 1 more. Started Nov 2016; status: terminated.
02
Drugs
durvalumab
03
Conditions
urothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT02891161.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02891161.